Het RIVMRijksinstituut voor Volksgezondheid en Milieu organiseert elk jaar de RVPRijksvaccinatieprogramma Onderzoeksdag. Deze dag is primair gericht op onderzoekers van instituten en universiteiten die zich bezighouden met onderzoek op het gebied van vaccins, vaccinatie en het vaccinatieprogramma. Ook artsen betrokken bij het Rijksvaccinatieprogramma zijn welkom.
RVP Onderzoeksdag 2019
|
RVP Onderzoeksdag 2018
In 2018 wordt de RVPRijksvaccinatieprogramma Onderzoeksdag niet georganiseerd.
RVPRijksvaccinatieprogramma in beweging! Nieuwe ontwikkelingen voor jong en oud.
Vrijdag 10 november 2017 organiseert het RIVMRijksinstituut voor Volksgezondheid en Milieu de 7e RIVM RVP Onderzoeksdag, waarvoor we je weer van harte uitnodigen. Ook dit jaar geven we aandacht aan huidige ontwikkelingen op het gebied van het Rijksvaccinatieprogramma van jong tot oud, zoals rotavirusvaccinatie, maternale kinkhoestvaccinatie, pneumokokkenvaccinatie, meningokokkenvaccinatie en HPV-vaccinatie.
Sprekers
| Patricia Bruijning, pediatrician, epidemiologist, Julius Center for Health Sciences and Primary Care, UMCUniversitair Medisch Centrum Utrecht / National Institute for Public Health and the Environment (RIVM) |
|
D. Barug, doctor researcher, |
|
M. van der Heiden, PhD student, |
| A.A.I. Palmu, MD, PhD, research manager, National Institute for Health and Welfare, Finland |
|
A.J. van Hoek, senior researcher, |
|
S.N. Ladhani, |
| M.J. Knol, MSc, PhD, epidemiology, National Institute for Public Health and the Environment (RIVM) |
|
Dr. A.J. King, Head of department virology of the vaccination program, molecular virologist, |
|
Dr. Johannes A. Bogaards, |
Agenda
| 09.30-09.35 | Welcome | Lieke Sanders |
| 09.35-10.00 | Assessing the public health benefits of the National Immunization Programme: expenditures, prevented morbidity, and prevented mortality | Jacco Wallinga |
| 10.00-10.10 | Discussion |
| 10.10-10.35 | Rotavirus Vaccination: New developments and Policy | Patricia Bruijning |
| 10.35-11.00 | Maternal pertussis vaccination and later start of infant vaccinations | Daantje Barug |
| 11.00-11.15 | Strengthening memory immunity in elderly by vaccination of middle-aged adults | Marieke van der Heiden |
| 11.15-11.25 | Discussion |
| 11.25-12.00 | Coffee break |
| 12.00-12.30 | Pneumococcal conjugate vaccines; full public health impact or cherry picking | Arto Palmu |
| 12.30-12.55 | Vaccinating the elderly against pneumococcal disease, a modelling and health economic perspective | Albert Jan van Hoek |
| 12.55-13.05 | Discussion |
| 13.05-14.00 | Lunch |
| Meningococcal disease | |
| 14.00-14.40 |
1. The UK infant meningococcal B (MenB) immunisation programme | Shamez Ladhani 2. Emergency introduction of the teenage meningococcal ACWY (MenACWY) | Shamez Ladhani |
| 14.40-14.55 | Invasive meningococcal disease in the Netherlands | Mirjam Knol |
| 14.55-15.05 | Discussion |
|
15.05-15.35 |
Coffee break |
| HPV | |
| 15.35-16.05 | HPV surveillance in the Netherlands | Audrey King |
| 16.05-16.35 |
Informing HPV vaccination strategy about target groups: girls-only, gender-neutral, catch-up and selective adult vaccination | Hans Bogaards |
| 16.35-16.45 | Discussion |
| 16.45-17.00 | Closure |
| 17.00-18.00 | Drinks |
Presentaties RVP Onderzoeksdag 2017
RVP Onderzoeksdag 2016
Het thema van de dag was: Vaccinatie in de 21e eeuw: Ontwikkelingen en uitdagingen
Presentaties RVP Onderzoeksdag 2016
Agenda
|
08.15 |
Registratie |
| 09.00 | Opening en welkom |Lieke Sanders |
| RS virus Nieuwe vaccins voor de nabije toekomst |
|
| 09.10-09.40 | Global burden of RSV disease in infants | Harish Nair, The University of Edinburgh |
| 09.40–10.20 | RSV immunisatie nu en in de toekomst Fifty-odd novel vaccines against RSV bronchiolitis - how to move forward | Louis Bont, UMCU |
| 10.20-10.30 | Discussie |
| 10.30-11.00 | Pauze |
| Meningokokken Vaccins voor vandaag of morgen? |
|
| 11.00-11.30 | Ervaringen met MenW en meningokokken ACYW vaccinatie in de UK Controlling the MenW outbreak in England | Helen Campbell, Public Health England |
| 11.30-11.50 | Meningokokkenziekte in Nederland: copy conforme? Invasive meningococcal disease in the Netherlands: increase in serogroup W disease | Mirjam Knol, RIVMRijksinstituut voor Volksgezondheid en Milieu |
| 11.50-12.05 | Meningokokken immunologie na boostervaccinatie bij adolescenten Immunological responses to adolescent (booster) vaccination | Mariette van Ravenhorst, RIVM |
| 12.05-12.20 | Discussie |
| 12.20-13.30 | Pauze |
| Kinkhoest Vaccins van vandaag of morgen? |
|
| 13.30-14.00 | Kinkhoestvaccins en onderzoek Why is immune memory to pertussis failing and what can we do about it? | Dimitri Diavatopoulos, Radboud Universiteit Nijmegen |
| 14.00-14.30 | Kinkhoest bij prematuren en maternale vaccinatie Pertussis in preterms and maternal pertussis immunization; new insights | Nicoline van der Maas, RIVM |
| 14.30-14.50 | Adaptatie van Bordetella pertussis onder vaccinatiedruk Vaccine-driven adaptation of Bordetella pertussis | Marjolein van Gent, RIVM |
| 15.00 - 15.20 | Pauze |
| Mazelen Morgen anders? |
|
| 15.20-15.50 | Review mazelenvaccinatie Measles: Global epidemiology and opportunities for eradication | Laura Nic Lochlainn, RIVM |
| 15.50-16.10 | Mazelen epidemie en BMRBof, mazelen, rodehond-0 (vaccin)effectiviteit Vaccine effectiveness of early MMR vaccination among 6-14 month-old infants during an epidemic in the Netherlands | Tom Woudenberg, RIVM |
| 16.10-16.30 | Immunologie van BMR-0 Antibody response after MMR-0 vaccination |Iris Brinkman, RIVM |
| 16.30-16.40 | Discussie |
| 16.40-16.50 | Afsluiting | Lieke Sanders |
| 16.50-18.00 | Napraten en borrel |
Theme of the day: CHALLENGES IN THE POST-VACCINATION ERA
The National Immunisation Programme of the Netherlands has drastically reduced disease morbidity and mortality in children. However, some of the target diseases are not yet under control. Also, as diseases disappear, the side effects of vaccination are weighed differently by the public. This has a negative influence on the general acceptance of vaccinations. Obviously, there are ongoing challenges to be dealt with.
The morning programme consists of lectures on the impact of vaccination over the years and the lessons learned:
- Pertussis is one of the target diseases in the immunisation programme that is not under control. Changes in the pertussis bacteria and the switch to acellular vaccines have failed to warrant sufficient protection. This poses a major, sometimes mortal risk to unvaccinated newborns. The UK has gained experience with maternal pertussis vaccinations and they will share present their results with us.
- We will present an evaluation of unfavourable/harmful events that occurred after vaccination and its consequences for a vaccination programme.
- Over the past decades tremendous progress has been made toward the eradication of polio worldwide. We will give you an update of the current situation and a cautious glance of the future.
Download presentaties RVP Oonderzoeksdag 2015
Agenda
|
08.15 |
Registration |
|
|
09.00 |
Lieke Sanders |
Welcome |
|
09.15 |
Liz Miller, PH England |
Experience with maternal pertussis immunisation in England |
| 10.00 |
|
Discussion |
|
10.15 |
Maarten van Wijhe |
The impact of vaccination programmes on mortality burden among children and young adults in the Netherlands over the 20th century |
|
|
|
|
|
11.00 |
|
Pauze |
|
|
|
|
|
11.30 |
Patricia Vermeer |
Risk and Benefit, a dynamic balance |
|
12.00 |
Harrie van der Avoort |
A world free of polio after sixty years of vaccination? |
|
|
|
|
|
12.30 |
|
Lunch |
|
|
|
|
|
13.30 |
Hester de Melker |
Five years of HPV vaccination; safety and effectiveness |
|
14.00 |
Michiel van Boven |
Health effects and cost-effectiveness of varicella vaccination are shaped by the impact on herpes zoster |
|
14.30 |
Anne Wyllie |
The pneumococcal reservoir: improving carriage surveillance |
|
|
|
|
|
15.00 |
|
Pauze |
|
|
|
|
|
15.30 |
Saskia van der Lee |
Extensive limb swelling after the booster vaccination at 4 years of age: immunologically explained? |
|
16.00 |
Oliver Wicht |
Perspectives on vaccination against respiratory syncytial virus |
|
16.30 |
Lieke Sanders |
Closure |
|
|
|
|
|
16.45 |
|
Drinks |
Theme of the day: ‘Vaccination for life’
In bygone days we spoke of “childhood infections” (“kinderziekten”). The explanation is that these infections were in general so prevalent that children encountered these early in life and that these infections left them with seemingly life-long protection, so these diseases hardly occurred beyond childhood. Will vaccination, mimicking infection without causing the actual disease, also induce life-long protection? After more than half a century of vaccination, changing the epidemiology of the target diseases, we face new challenges in the control of vaccine-preventable diseases aiming at persistent protection.
The theme of the morning programme of this year’s Vaccine Preventable Diseases Research Day (the so-called “RVPRijksvaccinatieprogramma Onderzoeksdag”) will be the duration of protection. Several aspects of this duration of protection like immunological mechanisms, epidemiology and the implications for the National Immunisation Programme will be topics of the programme. In the afternoon the results of several recent vaccination studies will be presented, such as pneumococcal vaccination of the elderly (CAPITA study) and impact of pneumococcal vaccination of infants on the elderly, vaccination during the measles epidemic, and the attitude towards vaccination.
Agenda
|
08.15 |
Reception & registration |
|
09.00 |
Welcome | Marina Conyn |
|
09.15 |
Evolving vaccine schedules to maintain long term protection | Ray Borrow |
|
10.00 |
Duration of protection against pertussis in view of vaccination history | Wanda Han |
|
10.20 |
Vaccination for life: long-term effects of vaccination on host and pathogen | Dimitri Diavatopoulos |
|
10.50 |
Discussion |
|
|
|
|
11.00 |
Coffee/tea break |
|
|
|
|
11.30 |
Duration of protection: insights from mathematical modelling|Jacco Wallinga |
|
11.50 |
MenC booster vaccination in adolescents to maintain herd immunity | Susanne Stoof |
|
12.10 |
Mumps in vaccinated adolescents | Sigrid Gouma |
|
|
|
|
12.30 |
Lunch |
|
|
|
|
13.30 |
Vaccination against pneumococcal disease in the elderly (Capita-study) | Marc Bonten |
|
14.00 |
Added value of vaccination against pneumococcal disease in elderly? | Mirjam Knol |
|
14.20 |
Discussion |
|
|
|
|
14.35 |
Coffee/tea break |
|
|
|
|
|
Measles epidemic in 2013/2014 |
|
15.05 |
MMR vaccine uptake during a measles outbreak in the Netherlands in 2013 | Laura Nic Lochlainn |
|
15.25 |
Clinical effectiveness and safety of early MMR-vaccination | Nicoline van der Maas |
|
15.45 |
Neutralising antibodies as a marker to find gaps in immunity against measles | Rob van Binnendijk |
|
16.05 |
Monitoring acceptance of vaccination: implications for communication | Liesbeth Mollema |
|
16.35 |
Closure | Marina Conyn |
|
|
|
|
16.40 |
Drinks |
Thema van de dag: 'Correlates of Protection: facts and fiction'
Het RIVMRijksinstituut voor Volksgezondheid en Milieu organiseert voor derde keer de jaarlijkse RIVM RVPRijksvaccinatieprogramma-onderzoeksdag. Deze dag is primair gericht op onderzoekers van instituten en universiteiten die zich bezighouden met onderzoek op het gebied van vaccins, vaccinatie en het vaccinatieprogramma. Ook artsen betrokken bij het Rijksvaccinatieprogramma (RVP) zijn welkom.
Het thema is dit jaar: ‘Correlates of Protection; facts and fiction.’ Dit onderwerp staat centraal in het ochtendprogramma. In het middagprogramma worden resultaten van RIVM-onderzoek ter evaluatie van het RVP, nieuwe vaccins en mogelijke wijzigingen van het vaccinatieprogramma gepresenteerd. Ook hierbij zullen Correlates of Protection aan de orde komen.
Thema van de dag is: ‘Vaccination, problems & promises’
Woensdag 28 november 2012 organiseerde het RIVMRijksinstituut voor Volksgezondheid en Milieu voor de tweede keer de RIVM RVPRijksvaccinatieprogramma-onderzoeksdag. Deze RVP-onderzoeksdag richt zich primair op onderzoekers van instituten en universiteiten die zich bezighouden met vaccinologisch onderzoek. Daarnaast zijn artsen verantwoordelijk voor het Rijksvaccinatieprogramma uitgenodigd. Op deze dag worden resultaten van RIVM-onderzoek ter evaluatie van het RVP én onderzoek van nieuwe vaccinaties gepresenteerd.